Vergoeding 2020-2024 voor ATC-subgroep N02CD : Cgrp-antagonisten
- Raming voor de totale Zvw-populatie
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| N02CD01 Erenumab (Aimovig ®) | 562.850 | 7.030.800 | 8.877.100 | 9.884.700 |
| N02CD02 Galcanezumab (Emgality ®) | 1.029.100 | 6.643.200 | 8.399.500 | 9.101.000 |
| N02CD03 Fremanezumab (Ajovy ®) | 352.570 | 5.351.700 | 8.978.700 | 13.395.300 |
| N02CD07 Atogepant (Aquipta ®) | . | . | . | 160.450 |
| Totaal | 1.944.520 | 19.025.700 | 26.255.300 | 32.541.450 |